Statera Biopharma

Statera Biopharma EBIT

The EBIT of Statera Biopharma (STAB) as of Nov 5, 2026 is -29.95 M USD. In the previous year, EBIT was -2.59 M USD — a change of 1,056.37% (lower).

EBIT

-29.95 MUSD

YoY

1,056.37%

Last updated:

In 2021, Statera Biopharma's EBIT was -29.95 M USD, a 1,056.37% increase from the -2.59 M USD EBIT recorded in the previous year.

The Statera Biopharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2014
-14.43 M USD
Jan 1, 2015
-10.79 M USD
Jan 1, 2016
-6.36 M USD
Jan 1, 2017
-5.60 M USD
Jan 1, 2018
-4.80 M USD
Jan 1, 2019
-2.36 M USD
Jan 1, 2020
-2.59 M USD
Jan 1, 2021
-29.95 M USD
The Statera Biopharma EBIT history
YEAREBITYoY
-29.95 MUSD+1,056.37%
-2.59 MUSD+9.75%
-2.36 MUSD-50.83%
-4.80 MUSD-14.29%
-5.60 MUSD-11.95%
-6.36 MUSD-41.06%
-10.79 MUSD-25.23%
-14.43 MUSD-36.07%
-22.57 MUSD-24.89%
-30.05 MUSD+19.67%
-25.11 MUSD+133.80%
-10.74 MUSD+68.34%
-6.38 MUSD-55.54%
-14.35 MUSD-44.68%
-25.94 MUSD+249.60%
-7.42 MUSD+197.99%
-2.49 MUSD-1.19%
-2.52 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Statera Biopharma Revenue

Statera Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2014
3.70 M USD
-14.43 M USD
1.63 M USD
Jan 1, 2015
2.71 M USD
-10.79 M USD
-12.64 M USD
Jan 1, 2016
3.52 M USD
-6.36 M USD
-2.66 M USD
Jan 1, 2017
1.95 M USD
-5.60 M USD
-9.71 M USD
Jan 1, 2018
1.14 M USD
-4.80 M USD
-3.61 M USD
Jan 1, 2019
1.11 M USD
-2.36 M USD
-2.65 M USD
Jan 1, 2020
260,000.00 USD
-2.59 M USD
-2.40 M USD
Jan 1, 2021
1.49 M USD
-29.95 M USD
-101.85 M USD

Statera Biopharma Margins

Statera Biopharma stock margins

The Statera Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Statera Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Statera Biopharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2014
67.11 %
-390.00 %
44.05 %
Jan 1, 2015
67.11 %
-398.15 %
-466.42 %
Jan 1, 2016
67.11 %
-180.68 %
-75.57 %
Jan 1, 2017
67.11 %
-287.18 %
-497.95 %
Jan 1, 2018
67.11 %
-421.05 %
-316.67 %
Jan 1, 2019
67.11 %
-212.61 %
-238.74 %
Jan 1, 2020
67.11 %
-996.15 %
-923.08 %
Jan 1, 2021
67.11 %
-2,010.07 %
-6,835.57 %

Statera Biopharma Stock analysis

What does Statera Biopharma do? Statera Biopharma develops immunotherapies targeting autoimmune diseases, neutropenia/anemia, emerging viruses, and cancers using a proprietary platform that rebalances the immune system. The company focuses on TLR agonists and antagonists, including Entolimod and GP532, with clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205). Statera generates revenue through clinical development and potential future product sales, targeting healthcare providers and pharmaceutical partners for its therapies. The company’s primary segments are autoimmune therapies, oncology, and infectious disease treatments, with Entolimod serving as a key product in hematology and immune modulation. Statera Biopharma’s business model relies on advancing its clinical-stage therapies through partnerships and licensing deals, with Entolimod and STAT-201 as flagship programs. The company’s TLR platform enables targeted immune responses, attracting interest from biopharmaceutical firms seeking innovative treatments. Revenue streams include milestone payments from collaborators and potential royalties on future commercialized products, focusing on segments such as autoimmune disorders, cancer, and viral infections. The firm’s development pipeline includes STAT-401 for pancreatic cancer and STAT-205 for COVID-19, positioning it for growth in high-demand therapeutic areas. The company’s products Entolimod and GP532 are central to its strategy, with Entolimod targeting hematology and immune-related conditions. Clinical programs like STAT-201 for Crohn’s disease and STAT-401 for pancreatic cancer represent key revenue opportunities. Statera Biopharma’s target customers include hospitals, clinics, and pharmaceutical companies, with a focus on delivering therapies for autoimmune, inflammatory, and cancer-related conditions. The business model emphasizes clinical progress to secure partnerships and generate future sales in the biopharmaceutical market. Statera Biopharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Statera Biopharma's EBIT

Statera Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Statera Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Statera Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Statera Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Statera Biopharma stock

EBIT of Statera Biopharma is -29.95 M USD in 2021.

EBIT of Statera Biopharma changed from -2.59 M USD to -29.95 M USD, representing a 1,056.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Statera Biopharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Statera Biopharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Statera Biopharma

All Key Metrics — Statera Biopharma